Business
Axcan Pharma to present at Merrill Lynch Global Healthcare Conference
Axcan Pharma to present at Merrill Lynch Global Healthcare Conference.
About this update from Trailbreaker Resources Ltd
[{"type":"text","content":"\n\n\n\n\nTSX SYMBOL (Toronto Stock Exchange): AXP\nNASDAQ SYMBOL (NASDAQ National Market): AXCA\n\nMONT SAINT-HILAIRE, QC, Jan. 31 /CNW Telbec/ - Axcan Pharma Inc. (\"Axcan\"\nor the \"Company\") today announced that on Tuesday, February 7, 2006, president\nand chief executive officer, Frank A.G.M. Verwiel, M.D., will present an\noverview of the Company at Merrill Lynch's Global Pharmaceutical,\nBiotechnology and Medical Device Conference held in New York, NY. This\npresentation will take place at 10:20 A.M. ET.\nA webcast of Axcan's presentation can also be accessed via the Company's\nwebsite at www.axcan.com.\n\nAxcan is a leading specialty pharmaceutical company involved in the field\nof gastroenterology. The Company markets a broad line of prescription products\nsold for the treatment of symptoms in a number of gastrointestinal diseases\nand disorders such as inflammatory bowel disease, irritable bowel syndrome,\ncholestatic liver diseases and complications related to cystic fibrosis.\nAxcan's products are marketed by its own sales force in North America and\nEurope. Its common shares are listed on the Toronto Stock Exchange under the\nsymbol \"AXP\" and on the NASDAQ National Market under the symbol \"AXCA\".\n\n\"Safe Harbor\" statement under the Private Securities Litigation Reform\nAct of 1995.\n\nThis release contains forward-looking statements, which reflect the\nCompany's current expectations regarding future events. To the extent any\nstatements made in this release contain information that is not historical,\nthese statements are essentially forward looking and are often identified by\nwords such as \"anticipate,\" \"expect,\" \"estimate,\" \"intend,\" \"project,\" \"plan\"\nand \"believe.\" Forward-looking statements are subject to risks and\nuncertainties, including the difficulty of predicting FDA and other regulatory\napprovals, acceptance and demand for new pharmaceutical products, the impact\nof competitive products and pricing, new product development and launch,\nreliance on key strategic alliances, availability of raw materials, the\nregulatory environment, fluctuations in operating results, the protection of\nour intellectual property and other risks detailed from time to time in the\nCompany's filings with the Securities and Exchange Commission and the Canadian\nsecurities regulatory authorities.\n\n\n",...